Name | Cat# | Price (1ml, USD) | Add to cart |
MagVigen™ – PD-L1 On-Bead ELISA Kit Product Sheet |
KE7101 | $560 for 96 assays |
![]() |
MagVigen™ – HER2 On-Bead ELISA Kit Product Sheet |
KE7102 | $560 for 96 assays |
![]() |
MagVigen™ – EGFR On-Bead ELISA Kit Product Sheet |
KE7103 | $560 for 96 assays |
![]() |
MagVigen™ – CEA On-Bead ELISA Kit Product Sheet |
KE7104 | $560 for 96 assays |
![]() |
MagVigen™ – VEGF On-Bead ELISA Kit Product Sheet |
KE7105 | $560 for 96 assays |
![]() |
MagVigen™ – TNF-α On-Bead ELISA Kit Product Sheet |
KE7106 | $560 for 96 assays |
![]() |
MagVigen™ – TGF-β On-Bead ELISA Kit | KE7107 | $560 for 96 assays |
![]() |
MagVigen™ – IFN-γ On-Bead ELISA Kit | KE7108 | $560 for 96 assays |
![]() |
MagVigen™ – InterLeukin- On-Bead ELISA Kits | KE7109 | ||
Human ERBB2/HER2 (Research Grade Cetuximab Biosimilar) Antibody Recombinant Monoclonal Antibody For Research Use Only (Validated by NVIGEN’s immunoassay) |
AB7102 | $150 package size 100 ug |
![]() |
Human EGFR (Research Grade Cetuximab Biosimilar) Antibody Recombinant Monoclonal Antibody For Research Use Only (Validated by NVIGEN’s immunoassay) |
AB7103 | $150 package size 100 ug |
![]() |
Human VEGF (Research Grade Bevacizumab Biosimilar) Antibody Recombinant Monoclonal Antibody For Research Use Only (Validated by NVIGEN’s immunoassay) |
AB7105 | $150 package size 100 ug |
![]() |
Overview of On-Beads ELISA Assay
Magnetic nanoparticles are an increasingly common feature in diagnostics. With their ability to disperse evenly throughout a medium, the reactive surface area of functionalized nanoparticles exhibit superior kinetics in capturing target analytes with high efficiency. NVIGEN’s nanoparticle-based ELISA assays are thus rapid, highly sensitive tests with shorter incubation times that enable a smoother workflow, provide superior results, and support multiplex assays.
NIVGEN On-Bead-ELISA Workflow
Figure 2. Basic Workflow for On-Bead ELISA Assay.
- Antigen capture: Mix sample with antibody-conjugated beads, which will rapidly capture analyte such as sPD-L1.
- Wash: Place plate on an NVIGEN magnetic plate (cat#A20008) and wash plasma and other proteins from the plate. The NVIGEN magnetic plate is designed to magnetize the beads into a pellet so that the supernatant can be easily removed.
- Incubate with enzyme-bound detection antibody: Mix detection antibody in assay diluent and incubate with the beads.
- Wash: Wash excess enzyme from the plate, again using the NVIGEN magnetic plate to pellet the beads between wash steps.
- Add Detection Solution: Add detection solution, pipet up and down to mix, incubate for 15 minutes for the reaction to proceed.
- Transfer detection solution to new plate, read on plate reader: Transfer the supernatant to a clean plate and read the results using a standard plate reader.
Performance:
Our bead-based PDL1 assay notably exhibits over 6x the sensitivity of a standard ELISA in which capture antibodies are adsorbed onto a plate surface. Additionally, due to the optimal bead kinetics, our assay can be performed in a fraction of the time compared to competing assays, with a lower limit of detection at 0.1 ng/mL.
Figure 3. On-Bead Elisa PD-L1 Assay Performance.
Comparison of standard on-plate versus on-bead ELISAs done in human plasma. On-Bead ELISAs demonstrate superior linearity, signal, and sensitivity. Low-end detection threshold is approximately 100 pg/mL with 200 uL of human plasma sample.
Additional Examples of On-Bead ELISA Assay Performance
Figure 4. EGFR assay performance, on-plate vs. on-bead.
Figure 5. HER2 assay performance, on-plate vs. on-bead.
Figure 6. CEA assay performance, on-plate vs. on-bead. CEA (Cancer Embryonic Antigen), more specifically known as CEACAM5 (CarcinoEmbryonic Antigen-related Cell Adhesion Molecule 5), or CD66e, is a biomarker of a multitude of cancers, particularly colorectal cancers1. Its role in breast cancer is an active field of research2. Progressively elevated levels of CEA have been found to correlate with both the progressive stage as well as the grade of breast cancer3.
Reference
- Beauchemin N, Arabzadeh A (December 2013). “Carcinoembryonic antigen-related cell adhesion molecules (CEACAMs) in cancer progression and metastasis“. Cancer and Metastasis Reviews. Volume 32 p643–671.
- Shao Y, Sun X (2015). “Elevated Levels of Serum Tumor Markers CEA and CA15-3 Are Prognostic Parameters for Different Molecular Subtypes of Breast Cancer“. PLoS ONE 10(7).
- Al-Nafakh Z, Al-Dujaili (2020). “Assessment of Cancer Embryonic Antigen (CEA) Biomarker in Women with Breast Cancer Disease“. AIP Conference Proceedings 2290.
Related Products
- MagVigen™ – Streptavidin, protein capture kit (Cat # K21005P)
- MagVigen™ – anti EpCAM CTC Capture Kit (Cat # K51001)
- MagVigen™ – anti CD45 Cell Capture Kit (Cat# K51002)
- MagVigen™ – anti PD L1 Biomarker Capture Kit (Cat # K51010)
- MagVigen™ – anti HER2 Biomarker Capture Kit (Cat #K51011)
- MagVigen™ – anti EGFR Biomarker Capture Kit (Cat #K51012)
- MagVigen™ – Protein A Kit (Cat # K21003)
- MagVigen™ – Protein G Kit (Cat # K21004)
- MagVigen™ – protein A/G kit (Cat #K21009)